116株无亲缘关系的金黄色葡萄球菌临床分离株中，环丙沙星、氧氟沙星、左氧氟沙星、司帕沙星和莫西沙星（BAY 12 - 8039）的最低抑菌浓度（MIC）与grlA、grlB、gyrA和gyrB基因突变之间的关系
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
作者信息
Schmitz F J, Hofmann B, Hansen B, Scheuring S, Lückefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz H P, Köhrer K, Jones M E
机构信息
Institute for Medical Microbiology and Virology, Heinrich-Heine University, Düsseldorf, Germany.
出版信息
J Antimicrob Chemother. 1998 Apr;41(4):481-4. doi: 10.1093/jac/41.4.481.
The in-vitro activities of five fluoroquinolones were tested against 70 ciprofloxacin-resistant and 46 ciprofloxacin-susceptible unrelated isolates of Staphylococcus aureus. All 116 S. aureus isolates were studied for the presence of mutations in the grl and gyr loci. The order of efficacy of the fluoroquinolones tested, from least to most active, was: ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039), in response to all characterized mutations in grlA, grlB, gyrA and gyrB. Moxifloxacin was active against most S. aureus isolates tested (MIC90 = 1 mg/L for ciprofloxacin-resistant isolates) and was less influenced by known mutations.
对5种氟喹诺酮类药物针对70株耐环丙沙星和46株对环丙沙星敏感的无关金黄色葡萄球菌分离株进行了体外活性测试。对所有116株金黄色葡萄球菌分离株研究了grl和gyr位点的突变情况。所测试的氟喹诺酮类药物的疗效顺序，从最低活性到最高活性依次为：环丙沙星、氧氟沙星、左氧氟沙星、司帕沙星和莫西沙星（BAY 12 - 8039），这是针对grlA、grlB、gyrA和gyrB中所有已鉴定的突变而言。莫西沙星对大多数所测试的金黄色葡萄球菌分离株有活性（耐环丙沙星分离株的MIC90 = 1mg/L），并且受已知突变的影响较小。
Zotero 插件